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Background: Up to 40% of patients initially diagnosed with clinically-confined renal cell carcinoma (RCC) and who
undergo curative surgery will nevertheless relapse with metastatic disease (mRCC) associated with poor long term
survival. The discovery of novel prognostic/predictive biomarkers and drug targets is needed and in this context the
aim of the current study was to investigate a putative caveolin-1/ERK signalling axis in clinically confined RCC, and
to examine in a panel of RCC cell lines the effects of caveolin-1 (Cav-1) on pathological processes (invasion and
growth) and select signalling pathways.
Methods: Using immunohistochemistry we assessed the expression of both Cav-1 and phosphorylated-ERK (pERK)
in 176 patients with clinically confined RCC, their correlation with histological parameters and their impact upon
disease-free survival. Using a panel of RCC cell lines we explored the functional effects of Cav-1 knockdown upon
cell growth, cell invasion and VEGF-A secretion, as well Cav-1 regulation by cognate cell signalling pathways.
Results: We found a significant correlation (P = 0.03) between Cav-1 and pERK in a cohort of patients with clinically
confined disease which represented a prognostic biomarker combination (HR = 4.2) that effectively stratified
patients into low, intermediate and high risk groups with respect to relapse, even if the patients’ tumours displayed
low grade and/or low stage disease. In RCC cell lines Cav-1 knockdown unequivocally reduced cell invasive capacity
while also displaying both pro-and anti-proliferative effects; targeted knockdown of Cav-1 also partially suppressed
VEGF-A secretion in VHL-negative RCC cells. The actions of Cav-1 in the RCC cell lines appeared independent of
both ERK and AKT/mTOR signalling pathways.
Conclusion: The combined expression of Cav-1 and pERK serves as an independent biomarker signature with
potential merit in RCC surveillance strategies able to predict those patients with clinically confined disease who will
eventually relapse. In a panel of in-vitro RCC cells Cav-1 promotes cell invasion with variable effects on cell growth and
VEGF-A secretion. Cav-1 has potential as a therapeutic target for the prevention and treatment of mRCC.
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Caveolin-1 (Cav-1) is a regulator of signal transduction
events and cytoskeletal dynamics [1,2]. In some cell types
it interacts with multiple members of the EGF-R/RAS/
ERK and PI3-K/AKT pathways to modify signalling activ-
ity [3]. At least in preclinical models Cav-1 is shown to
modulate a number of signalling pathways to promote
and/or suppress the malignant phenotype [4,5]. For ex-
ample, Cav-1 has been shown to facilitate both ERK and
AKT signalling in cancer cells derived from colon [6],
prostate [7], epidermis [8] and smooth muscle [9], and is
associated with promoting cell invasion, proliferation,
angiogenesis and multi-drug resistance. However, the role
of Cav-1 in malignancy is both complex and multifaceted
with both tumour suppressor and oncogenic properties
described in what appears to be a disease-specific and
context-dependent manner. For example, the elevated
levels of Cav-1 in clinical tumour tissue from prostate
[10], bladder [11] and multiple myeloma [12] is unequivo-
cally linked with metastasis and poor prognosis. Mean-
while in carcinomas of the breast [13,14], colon [15,16]
and lung [17-19] both the loss and gain of Cav-1 have
been associated with tumour progression.
Renal Cell Carcinoma (RCC) is a highly vascularised
heterogeneous group of tumours with the clear cell
phenotype the most common and aggressive form [20].
At diagnosis approximately one-third of RCC patients
present with metastatic disease (mRCC) [21] which is
highly resistant to conventional treatments and which is
associated with a very poor long-term survival [22]. The
mainstay of treatment for clinically confined RCC is cura-
tive radical nephrectomy, however, even in this group of
patients upto 40% will eventually develop mRCC [22].
Identifying patients at high risk of relapse is compromised
by the varying clinical course of patients whose primary
tumours are of similar histological stage and grade [23]
but which must display significant molecular heterogen-
eity. As such prognostication and post-operative patient
surveillance with early instigation of molecular therapies
would benefit from mechanistically-based biomarkers that
accurately reflect the clinical significance of different RCC
primary tumour biologies.
Previously, we and others have shown Cav-1 [24-26]
to correlate with the aggressive features of RCC and pre-
dict poor disease-free survival (DFS) in patients present-
ing with clinically confined disease. We have also shown
pERK-1/2 to be a significant predictor of poor DFS in
RCC and shown it to serve as an independent prognostic
biomarker [27]. We have also revealed co-operation be-
tween Cav-1 and the AKT/mTOR pathway in advanced
RCC [28]. However, the importance and clinical signifi-
cance of Cav-1 and pERK co-expression and co-operation
is unknown and a full understanding of the roles of Cav-1
in RCC patho-biology remains to be determined. In thisstudy we show a positive correlation in primary RCC
tumours between the over-expression of Cav-1 and pERK-
1/2, their co-expression in localised tumours a powerful
biomarker combination able to stratify patients into low,
intermediate and high risk of developing mRCC including
recognising high risk patients whose primary tumours
displayed low grade and/or low stage disease. We also
found significant concordance in the expression of Cav-1
and pERK-1/2, either alone or combined, between
matched primary and metastatic tumours. Consistent with
pro-aggressive features of Cav-1 in the clinical data we
show in a panel of RCC cell lines of varying genetic back-
ground that Cav-1 levels directly influence RCC cell
growth and cell invasion, and its expression is associated
with pro-angiogenic potential in VHL-negative RCC cells.
However, under the same experimental conditions we
found no direct control of either ERK upon Cav-1 expres-
sion or the reverse, i.e. Cav-1 upon ERK. Further, both the
PI3-K/AKT/mTOR and the RANKL/NFkappB signalling
modules, two important pathways in RCC, were also
found to be without effect upon Cav-1 expression. These
results corroborate Cav-1 to have direct effects on RCC
patho-biology and support Cav-1 as a valuable biomarker
in RCC especially when incorporated with other markers
of biologically relevant signalling pathways such as acti-
vated ERK.
Material and methods
Human renal cell carcinoma cell lines and culture
Caki-1 and A498 cells were provided by Professor R.A.
Blaheta (Johann Wolfgang Goethe University, Frankfurt)
while 786-O and RCC4 cells were from Professor A.
Harris (Radcliffe Hospital, Oxford). The caki-2 and
ACHN cell lines were obtained from E.C.A.C.C. (Porton
Down, UK). The caki-1, caki-2 and A498 cell lines were
routinely cultured in RPMI medium (Invitrogen), while
RCC4, 786-O, and ACHN cells were cultured in DMEM
(Invitrogen). Both media were supplemented with 10%
FBS and 1% penicillin G (100 units/ml) and strepto-
mycin (100 μg/ml) and maintained in 5% CO2 at 37°C.
siRNA treatments
Using methods previously described [29] a siRNA duplex
(21 nucleotides) was used to down-regulate Cav-1 mRNA
(siRNA sequence 5′-AGACGAGCUGAGCGAGAAGUU-
3′) and a siRNA duplex (21 nucleotides) targeting the
non-mammalian firefly luciferase (GL2) (siRNA sequence
5′-AACGUACGCGGAAUACUUCGA-3′) was used as a
negative control. The duplexes were purchased from
MWG (Ebersberg, Germany) as unprotected, desalted and
purified siRNA.
For all transfection studies 786-O and A498 cells were
seeded at a density of 1.3 × 103 cells cm-2 and caki-1
cells at a density of 3 × 103 cells cm-2, in either a 6-well
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well format for growth assays. At 24 hrs post-seeding
the cells were transfected (Oligofectamine, Invitrogen)
with 50 pmoles siRNA targeting either Cav-1 or control
(luciferase). Following a 4 hr transfection period the cells
were supplemented with their respective culture me-
dium containing 10% FBS. At 3 days (72 hrs) post-
transfection (i.e. 98 hrs post-seeding) the cells were
either collected for invasion studies, harvested for West-
ern blot or evaluated for cell growth. Cell growth was
assessed by MTT and definitively by means of trypsin
dispersion of the cell monolayers with cell counts quan-
tified by a Coulter-counter (Luton, UK). Despite several
different transfection strategies an adequate and repro-
ducible siRNA-mediated Cav-1 down-regulation was not
achievable in RCC4 and ACHN cells.
Cell treatments
For the pharmacological inhibitor studies the cells were
seeded in 6-well and 24-well formats as described above.
At 24 hrs post-seeding the cells were treated with either
the mTOR inhibitor rapamycin (1 and 10 nM), the MEK
inhibitor PD98059 (10, 25 and 50 μm) or the PI3-K/AKt
inhibitor LY-294002 (10 and 50 μm); cells were incu-
bated in the drug of choice for 48 hrs or 72 hrs. Cells were
used for growth assay or harvested for immunoblot. For
the RANK-L studies cells were grown in a 6-well format
for 48 hrs in the presence of serum at which point they
were serum starved overnight (16 hrs). After this RANK-L
(100 ng/ml) was added and the cells then harvested at
24 hrs post-treatment for immunoblot.
Immunoblotting
Cells were seeded in a 6-well format as described above
and treated with either siRNA or the drug of choice. At
the indicated times post-treatment (24 to 72 hrs) cells
were lysed (15 min on ice) using ice-cold lysis buffer,
then centrifuged at 12,000 g for 15 min at 4°C. Total
protein concentrations were determined using the BC
BioRad protein assay kit (Bio-Rad, Hertfordshire, UK). Cell
lysates of equivalent total protein were denatured and
resolved on 12% SDS polyacrylamide gels and electro-
blotted onto 0.2 μm nitro-cellulose membrane (Schleicher
and Schuell, Dassel, Germany). Membranes were blocked
(1 hr) with blocking buffer consisting of 5% fat-free dry
milk in Tris buffered saline (TBS)-Tween 20 (0.05%)
(TBS-T; pH 7.5) and then incubated with the primary
antibody of choice for 16 hrs at 4 °C (1:1000 in blocking
buffer). All primary antibodies were from Cell Signalling
(New England Biolabs, Hertfordshire, UK) unless other-
wise stated: Cav-1, phospho-AKT (Ser473), total AKT,
phospho-S6 (Ser235/236), total S6, phospho-ERK-1/2
(Tyr42/44), total ERK, phospho-NF-KappaB-p65 (Ser536),
total NK-KappaB-p65, c-myc and β-actin. Cyclin D1 andα-tubulin were from Santa Cruz (USA). After primary anti-
body incubation the membranes were washed (6 × 5 min)
in TSB-T and then incubated for 1 hr at room temperature
with the required secondary IgG HRP-labelled antibody
(Cell Signalling) diluted 1/7000 in blocking buffer. Mem-
branes were again washed (6 × 5 min) in TSB-T and signals
detected using either SuperSignal™ WEST DURA or
FEMTO chemiluminescent substrate (Pierce, Chester, UK).
Signals were captured on ECL Hyperfilm, following be-
tween 1 and 30 min exposures and the film developed and
fixed as appropriate.
Renal cancer cell invasion assays
To evaluate the effects of Cav-1 silencing on RCC cell
invasion, cells were transfected with either anti-Cav-1
or control siRNA as described above. The invasion as-
says were conducted using TranswellTM cell culture
inserts (6.5 mm diameter, 8 μm pore size; Costar, sup-
plied by Fisher, UK). The upper surface of the inserts
were coated with Matrigel™ (0.4 μg/ml) in a sterile
tissue-culture hood and allowed to polymerise at 37°C
for 2 hrs prior to use. Cells treated with anti-Cav-1
or control siRNA were trypsinised (72 hrs post-
transfection) from the 6-well culture dishes and 5 × 104
cells re-suspended in 200 μl of culture media and
seeded into the upper chamber of the coated inserts
with 650 μl of culture media added to the bottom
chamber. Cell invasion was allowed to progress at 37°C
for 24 hrs after which the non-invasive cells and
Matrigel™ were gently removed from the upper surface
of the polycarbonate membrane using a cotton swab.
Cells that had invaded to the lower surface of the
membranes were fixed with 3.7% formaldehyde and
counterstained with 0.05% Hoeschst 33258 in PBS
(pH 7.4) for visualisation of nuclei. The Transwell
membranes were then removed from the insert and
mounted onto microscope slides (Vectashield™, Mo-
lecular Probes). Cell invasion was quantified by pho-
tographing the membranes and selecting five random
fields of view at x20 magnification. Cells were counted
and data plotted as a percentage of control for a mini-
mum of three independent experiments (each per-
formed in duplicate).
VEGF-A ELISA assay
For determination of VEGF-A secretion following Cav-1
knockdown, cells were cultured in a 6-well format and
treated with either anti-Cav-1 or control siRNA. At
72 hrs post-transfection the cell culture supernatants
were collected and the secreted levels of VEGF-A quan-
tified (Quantikine human VEGF-A ELISA kit; R&D Sys-
tems). Cells were harvested using lysis buffer and the
total VEGF-A levels present in the supernatants was
normalised to total cellular protein levels.
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This study was approved by the South East Wales Re-
search Ethics Committee. Two separate tissue microarrays
(TMA) were constructed. One consisted of 174 biopsy or
radical nephrectomy samples resected from patients with
clinically confined RCC as described in detail elsewhere
[27,28]. The other TMA consisted of a cohort of matched
primary and metastatic tumour specimens from 14 pa-
tients who had undergone surgery for removal of both pri-
mary and secondary tumours either simultaneously or at a
later date. In all of the above cases archival paraffin-
embedded tissue blocks, histology reports and slides were
available and for each tissue specimen used in the con-
struction of the TMA a block was selected that contained
a sample of peripheral tumour.
Construction of TMAs and immunohistochemistry for
Cav-1 and pERK-1/2 was undertaken using previously
published methodologies [27,28]. Briefly, single cores rep-
resentative of peripheral tumour (0.6 mm in diameter)
were punched from each donor block and transplanted
into a pre-moulded recipient paraffin wax block. Add-
itional ‘control’ cores were taken from normal renal tissue
(adjacent to some of the tumours) and from human pla-
centa. Serial sections were cut (4 μm thickness) from the
resulting TMA block and placed onto cleaned adhesive
glass slides (Superfrost Plus™).
Immunohistochemistry and scoring of sections
Array sections were deparaffinised and rehydrated using 3
sequential changes of 100% xylene and 100% ethanol, re-
spectively. Antigen retrieval for pERK-1/2 and Cav-1 was
undertaken as previously described [24,27,28]. Briefly, fol-
lowing removal of the paraffin wax the endogenous perox-
idase activity within the rehydrated tissue was quenched
using 3% hydrogen peroxide for 5 min. For pERK-1/2,
antigen retrieval consisted of microwaving TMA sections
in citric acid (0.1 M, pH 6.0) for 30 min, while for Cav-1
antigen retrieval consisted of boiling slides in citric acid
for 20 min. In all cases slides were cooled with running
tap water and after draining the array sections were equili-
brated (15 min at room temp) in either 100% normal hu-
man serum (pERK-1/2), or 0.6% BSA in Optimax™ wash
buffer (Cav-1). Primary rabbit anti-human pERK-1/2 and
Cav-1 antibodies were applied to each section at a dilution
of 1:25 and incubated for 16 hrs at 4°C. The next day sec-
tions were washed (4 × 1 min) with PBS and tissue immu-
nostained using the DAKO rabbit Envision™ staining
system (DAKO, Cambridge, UK) according to the manu-
facturers instructions. The TMA sections were counter-
stained with haematoxylin and finally mounted.
Tumour arrays were scored by a pathologist (DFRG) and
team members (LC and MG) without knowledge of other
pathological and clinical data. Expression of both Cav-1
and pERK-1/2 was assessed using a semi-quantitativecriteria as previously described [24,28] that accounted for
both the intensity of immunostain within tumour cells and
the percentage of tumour cells involved in each core. Scor-
ing was as follows: 0: no detectable immunostain in tumour
cells; 1: very light diffuse or focal light staining in tumour
cells; 2: light diffuse or moderate focal staining (may include
very small areas of heavy deposit); 3: tumour cores
containing areas of heavy staining in most or all tumour
cells. The scores were also converted to a simple binary
positive or negative score.
Statistical analysis
Statistical analysis of clinical data
Kaplan-Meier survival analysis was conducted to calculate
the disease-free survival (DFS) of patients with tumours
showing different scores for Cav-1 and pERK-1/2 staining.
This method was carried out using the log-rank test where
the first appearance of a metastasis was considered an
event and with patients considered censored who were last
seen alive without metastasis or who had died due to other
causes. Scores were converted to a binary simple covariate
(positive or negative) by thresholding to the most inform-
ative split on the Kaplan-Meier using the log-rank statis-
tical test. For Cav-1 a score of 0 and 1 was negative, and a
score of 2 and 3 was positive, while for pERK-1/2 the pres-
ence of any staining was considered positive. To test for
synergy between Cav-1 expression and pERK-1/2, com-
posite covariates were constructed and considered positive
if both Cav-1 and pERK-1/2 were expressed in the same
patient tumour and negative if expression of either of
these markers were negative. The association of biomarker
expression with conventional histological parameters (gra-
de, size, vascular invasion, stage, tumour type and capsular
invasion) was examined by cross tabulation and the chi-
squared test.
Multivariate survival analysis was carried out by Cox
regression using the “Enter or Forward Stepwise (Likeli-
hood)” function with covariates considered categorical.
We had already determined that the most influential co-
variates predicting disease-free progression of these pa-
tients are Fuhrman grade (grades 1 and 2, and grades 3
and 4 are pooled for analysis), any degree of vascular in-
vasion, tumour stage and histological evidence of renal
capsular invasion. When these covariates are taken into
account then tumour size and type had no influence on
DFS [30]. To determine if any of the biomarker covariates
had predictive value in the multivariate analysis, each co-
variate (both simple and composite) was added indivi-
dually in turn as an independent covariate to the Cox
regression analysis together with tumour grade, stage, vas-
cular invasion and invasion of the renal capsule; time to
event being the dependent variable.
To assess the concordance of both Cav-1 and pERK be-
tween primary and metastatic tumours the IHC staining
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categories according to the IHC phenotype of each core
(Cav+, pERK+; Cav-, pERK-; Cav+, pERK-; Cav-, pERK+)
with the presence of any staining considered positive. The
results from primary and metastatic tumours were cross
tabulated and the concordance assessed using the Pearson
contingency coefficient for paired observations and Kappa
statistic.
Statistical analysis of preclinical data Preclinical data
was analysed for two groups by T-test (unpaired) and by
more than two groups using ANOVA with post-hoc
tests Dunnett (comparisons to control) or Duncan
(comparisons across all groups). Statistical significance
at P ≤ 0.05.
Results
Combined Cav-1 and pERK-1/2 expression in localised RCC
tumours is a powerful predictor of metastasis
In clinically confined RCC we investigated the correl-
ation between Cav-1 and pERK-1/2 levels in primary tu-
mours and sought to examine if their combined
expression provided an enhanced prognostic indicator.
Of the samples that could be analysed for the combined
expression of Cav-1 and pERK-1/2 we found (Table 1)
42% (66/158) of patient tumours were positive for
Cav-1 (Figure 1A and 1B) and 35% (55/158) positive for
pERK-1/2 (Figure 1E and 1F). Cross tabulation revealed
the levels of Cav-1 and pERK-1/2 to be significantly
(P = 0.03) associated in the primary RCC tumours with
19% (29/158) of tumours showing co-expression. We
found the association between Cav-1 and pERK-1/2
only in the clear cell tumours, the most aggressive RCC
histological subtype. In the more indolent papillary car-
cinomas only 1 from 20 papillary tumours examined
were positive for both biomarkers (Table 2). The com-
bined expression of Cav-1 and pERK-1/2 correlated
with clear cell histology, high tumour stage and vascular
invasion (Table 2). Kaplan-Meier survival analysis revealed
patients with Cav-1 positive tumours had a mean DFS of
4.72 yrs versus 6.35 yrs (P = 0.013) for patients with Cav-1
negative tumours (Figure 1I). Patients with pERK-1/2
positive tumours had a DFS of 4.19 yrs versus 6.38 yrs
(P = 0.001) for pERK-1/2 negative tumours (Figure 1J).Table 1 Correlation of Cav-1 expression with pERK in
clinically confined RCC
p-ERK score Cav-1 negative Cav-1 positive
0 66 37
1 12 13
2 7 14
3 7 2
Statistically significant correlation P = 0.03.Notably, patients whose tumours simultaneously ex-
pressed Cav-1 and pERK-1/2 had a DFS of only 3.33 yrs
versus 6.17 yrs (P = 0.001) for tumours either negative
for one or both of the biomarkers (Figure 1K).
Stratifying patients into four subgroups according
to the expression of tumour Cav-1 and pERK-1/2
(Figure 1L) revealed that tumours lacking expression
of both Cav-1 and pERK-1/2 (C-/E- n = 64) were asso-
ciated with a good prognosis, i.e. DFS of 6.75 yrs and
an 80% probability of remaining disease-free at 5 yrs.
This compared to a DFS: of 5.27 yrs (P = 0.001) where
tumours were Cav-1 positive and pERK-1/2 negative
(C+/E- n = 26); of 4.77 yrs (P = 0.001) where tumours
were pERK-1/2 positive and Cav-1 negative (C-/E + n =
37), and of 3.33 yrs (P = 0.001) where tumours co-
expressed pERK-1/2 and Cav-1 (C+/E + n = 29). Not-
able was that the combined covariate of Cav-1 and
pERK-1/2 was able to identify patients at high risk of
relapse even if the patients’ tumour displayed low
grade (19/29 patients positive for the co-variate and re-
lapsing early had grade 1 or 2 tumours) and/or low
stage (11/29 had stage 1 or 2 tumours) disease. Multi-
variate Cox regression analysis (Table 3) found only
tumour grade (HR = 3.4; P = 0.001), capsular invasion
(HR = 5.4; P < 0.001) and combined expression of
Cav-1 and pERK-1/2 (HR = 4.2; P < 0.001) showed signifi-
cant association with reduced DFS. For Cav-1 alone the
HR =1.5 (95% CI 0.83-2.55; P = 0.18) while for pERK-1/2
alone the HR= 2.96 (95% CI 1.77-5.35; P = 0.001).
Concordance of Cav-1 and pERK-1/2 expression between
paired primary and metastatic tumours
Concordance of Cav-1 and pERK-1/2 expression was
assessed for 16 available matched primary and second-
ary (mRCC) tumours obtained from 14 different pa-
tients (Figure 2A to 2H; Table 4); in two patients
mRCC tissue was available from two sites. Six metasta-
ses were identified synchronously with the primary (4
lymph nodes; 2 adrenal), the others between 5 months
and 10 years after nephrectomy (2 liver, 2 bone, 2
brain, 2 adrenal, 1 lung, 1 soft tissue). In 14 of 16 pairs
Cav-1 expression was concordant (88%) between pri-
mary and metastatic tumours. In the two discordant
cases Cav-1 was expressed in the primary tumour but
not in the secondary. For pERK-1/2 a 94% level of con-
cordance was observed, with the one discordant case
showing a lack of pERK-1/2 in the secondary tumour
but a presence in the primary. For the combined covar-
iate of Cav-1/pERK-1/2, the primary and secondary tu-
mours pairs were 88% (14/16) concordant. For all three
cross-tabulations the agreement between primary and
metastatic tumours was significant (P < 0.01; Pearson
contingency coefficient) with Kappa values 0.64 to 0.74
indicating good to substantial agreement.
Figure 1 (See legend on next page.)
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Figure 1 Correlation of Cav-1 and pERK-1/2 expression in clinically confined RCC. Representative microarray cores of Cav-1 (1A to 1D) and
pERK-1/2 (1E to 1H) demonstrating positive and negative immunohistochemical staining in RCC. Typical cores are shown in low (1A,1C,1E,1G)
and high power (1B,1D,1F,1H). Kaplan-Meier metastasis-free survival of RCC patients (%) presenting with clinically confined disease whose
primary tumours were stratified by positive (+) or negative (−) expression of: Cav-1 (1I), pERK-1/2 (1J), co-expression of pERK-1/2 and Cav-1 [C+/E+] (1K),
and sub-analysis (1L) of patients who were: negative for both Cav-1 and pERK-1/2 [C-/E-]; positive for pERK-1/2 alone [C-/E+]; positive for Cav-1 alone
[C+/E-]; positive for both biomarkers [C+/E+]. Patients whose tumours expressed both pERK-1/2 and Cav-1.showed a significantly worse prognosis.
Note: Figures 1I and 1J relate to the univariate data for Cav-1 and p-ERK separately while Figures 1K and 1L relate to the co-variate data for Cav-1 and
p-ERK combined (Table 2).
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RCC cell lines where it modulates growth and drives
invasion
It has been previously reported [31] that Cav-1 expression in
the RCC cell line 786-O is regulated by VHL- and Hif-
dependent mechanisms. Here, at least under normoxic condi-
tions we found Cav-1 protein to be ubiquitously expressed in
a panel of primary and metastatic RCC cell lines (Figure 3A)
independent of VHL-status and indeed Hif expression, for ex-
ample, the ACHN (VHL-positive) cell line expresses negligible
Hif under normoxic conditions [32,33].
We explored the role of Cav-1 in RCC tumorigenic poten-
tial through in-vitro studies in the 786-O (VHL−/− and
PTEN−/−), A498 (VHL−/− and PTEN+/+) and caki-1
(VHL+/+ and PTEN+/+) cell lines all of which are of clear cell
origin. Treatment with anti-Cav-1 siRNAs consistently
resulted in a substantial reduction of Cav-1 protein (Figure 4B).Table 2 Association of the combined expression of Cav-1 and
Cav-1 (n = 165) p-ERK
- + -
Grade 1 & 2 69 47 75
Grade 3 & 4 25 24 29
P = 0.390
Tumour size <7 cm 49 29 55
>7 cm 45 42 49
P = 0.151
Vascular Invasion (−ve) 66 33 71
(+ve) 28 38 33
P = 0.002*
Capsular Invasion (−ve) 83 55 90
(+ve) 11 16 14
P = 0.063
Tumour Stage 1 44 21 50
Stage 2 31 14 28
Stage 3 & 4 19 36 26
P = 0.0001*
Non- papillary 76 67 84
Papillary 18 4 20
P = 0.011*
* Indicates that statistical significance achieved to at least P < 0.05 with actual P valThe knockdown in Cav-1 had varying effects on cell prolifera-
tion: no effect in 786-O cells (Figure 3D), increases (50%, P <
0.001) in A498 proliferation (Figure 3F) and decreases (30%,
P < 0.001) in caki-1 proliferation (Figure 3H). In contrast, silen-
cing of Cav-1 consistently reduced (P < 0.001) cell invasiveness
by 25% in the 786-O (Figure 3E), by 40% in A498 (Figure 3G)
and 70% in caki-1 (Figure 3I); typical fields of view for Matrigel
invasion by caki-1 cells are shown in Figure 3B (control siRNA)
and Figure 3C (anti-Cav-1 siRNA). While the effects of Cav-1
upon RCC cell proliferation were cell line dependent we found
an unequivocal role for Cav-1 in promoting RCC cell invasion.
Cav-1 down-regulation in RCC cells and effects on AKT/
mTOR and ERK signalling, and VEGF-A secretion
Cav-1 siRNA down-regulation resulted in an approxi-
mate 25% reduction (P = 0.05) in VEGF-A secretion
(Figure 4A) in the VHL-negative 786-O and A498 RCCpERK with conventional histological parameters in RCC
1/2 (n = 164) Cav-1/pERK1/2 (n = 158)
+ All other Tumours +/+
43 93 19
17 36 10
P = 0.951 P = 0.091
24 64 10
36 65 19
P = 0.112 P = 0.142
30 85 10
30 44 19
P = 0.021* P = 0.002*
47 109 22
13 20 7
P = 0.172 P = 0.267
17 55 7
15 38 4
28 36 18
P = 0.011* P = 0.002*
58 109 28
2 20 1
P = 0.004* P = 0.084
ue indicated in the Table itself.
Table 3 Multivariate Cox regression hazard model for time
to recurrence using a forward conditional selection method
Prognostic indices model (n) HR 95% CI P value
Grade 1 and 2 1
Grade 3 and 4 3.4 1.9-6.1 <0.001*
No capsular invasion present 1
Capsular invasion present 5.4 3.0-10.0 <0.001*
Cav-1 and p-ERK1/2 covariate negative 1
Cav-1 and p-ERK1/2 covariate positive 4.2 2.3-7.5 <0.001*
Covariates used include: tumour grade, stage, size, capsular invasion, vascular
invasion, Cav-1 and p-ERK1/2. The covariates of size, stage and vascular
invasion are rejected as not influential in the model by the selection method.
CI = 95% confidence limit, HR = Hazard Ratio *denotes significance P < 0.001.
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http://www.translational-medicine.com/content/11/1/255cell lines, while no significant effect upon VEGF-A se-
cretion was seen in the VHL-positive caki-1 cells. As
such Cav-1 appears to have a partial role in mediating
the secretion of VEGF-A in RCC cell types that maybe
dependent on VHL status. Substantial siRNA-mediated
suppression of endogenous Cav-1 protein expression
did not, however, have any noticeable effect on the
basal levels of phosphorylated AKT, phosphorylated
ERK and phosphorylated S6 (Figure 4B), at least under
non-stressed conditions, indicating that alterations to
AKT/mTOR and ERK signalling are not implicated in
the observed effects of Cav-1 down-regulation upon
cell growth, invasion and VEGF-A secretion. The levels
of the pro-proliferative cell cycle regulators, cyclin D1
and c-myc, also remained relatively unchanged in all
three RCC cell lines.Figure 2 Concordance of Cav-1 and pERK-1/2 between matched prim
matched primary and secondary tumours showing (i) positive concordance
and pERK-1/2 (2E-2H).AKT/mTOR and ERK down-regulation and RANKL
stimulation in RCC cells and effects on Cav-1 expression
In all three RCC cell lines the selective ERK inhibitor
PD98059 (treatment 72 hrs) led to dose-dependent reduc-
tions in pERK-1/2 (Figure 5A) and decreases in cell prolif-
eration (Figure 5B) but had no effect upon Cav-1
expression (Figure 5A), indicating Cav-1 is not serving as
an immediate downstream effector molecule of ERK-1/2.
Inhibition of mTORC1 with rapamycin (48 hr) resulted in
profound loss of pS6 (Figure 5C) and a significant reduc-
tion in cell proliferation (Figure 5D) with cell-type
dependent effects upon Cav-1, i.e. mTORC1 inhibition
caused a significant increase in the expression of Cav-1
protein in the PTEN-negative 786-O cells but no change
in either of the PTEN-positive cell lines, A498 and caki-1.
Treatment with the PI3-K inhibitor, LY-294002 (48 hrs),
resulted in inhibition in AKT signalling (Figure 5E) and re-
ductions in cell proliferation (Figure 5F), but was without
effect upon Cav-1 expression (Figure 5E).
RANKL is a member of the TNF superfamily and trig-
gers multiple signalling pathways. It has been associated
with tumour migration and metastasis in clinical cases of
RCC and invasion in in-vitro experiments with caki-1 cells
[34]. Following RANKL stimulation we observed in-
creased expression of phosphorylated ERK in all three
RCC cell lines accompanied by increased phosphorylated
NF-kappaB in A498 and caki-1 cells (Figure 5G). However,
no change in Cav-1 protein expression was observed in
any of the three RCC cell lines (Figure 5G) implying that
NF-kappaB does not serve as an immediate upstream ef-
fector for Cav-1 ,at least in this experimental setting.ary and secondary. Typical immunohistochemical staining in
of both Cav-1 and pERK-1/2 (2A-2D) and (ii) discordance of Cav-1
Table 4 Concordance of Cav-1 and pERK expression in matched primary and secondary metastatic tumours
Primary Metastatic Concordance
Biomarker Cav (−) Cav (+) pERK (−) pERK (+) Concordant / Total Kappa P
Cav (−) 3 0 14/16 0.67 P = 0.004
Cav (+) 2 11
pERK (−) 1 0 15/16 0.64 P = 0.006
pERK (+) 1 14
Cav(−) pERK(−) Cav(+) pERK(−) Cav(−) pERK(+) Cav(+) pERK(+)
Cav(−)/pERK(−) 0 0 0 0 14/16 0.74 P < 0.001
Cav(+)/pERK(−) 0 1 0 0
Cav(−)/pERK(+) 0 0 3 0
Cav(+)/pERK(+) 1 0 1 10
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The high relapse rates for patients diagnosed with clin-
ically confined disease, the treatment resistant nature
of mRCC, and the potential benefits of new molecular
therapies would lend support for improved measures
to identify patients at high risk [21,35]. At present
tumour grade and stage are the standard determinants
used in RCC to predict disease recurrence, although
both have limitations [23].
In this current study we show in primary RCC tumours
correlation between the increased expression of pERK-1/2
and Cav-1, and that their combined expression serves as a
more powerful predictor of disease recurrence than
tumour stage or pERK-1/2 or Cav-1 alone. Thus Cav-1
and pERK-1/2 appear to co-operate imparting a growth
and survival advantage to facilitate metastatic spread and
early relapse. The combined covariate of Cav-1 and pERK-
1/2 reliably stratified patients into low, intermediate or
high risk of relapse including patients that display low
grade and/or low stage disease. Further, we found bio-
marker concordance between matched primary and sec-
ondary tumour sites which supports similarities in
respective tumour biology and which may allow primary
tumour characterics to direct the choice of molecularly
targeted therapies in mRCC [36,37]. Collectively our
clinical findings would appear to have importance in the
identification of high-risk clear cell RCC patients, and
potentially subsequent instigation of treatment with
molecularly targeted therapies to prevent or delay dis-
ease recurrence, or indeed in the use of such therapies
in the treatment of mRCC itself. We did not identify an
association between Cav-1 and pERK in papillary RCC
tumours which contrasts to the report of Wang et al.
[31] who found Cav-1 and pERK-1/2 co-expression in
100% (8/8) of their papillary RCC patient cases. How-
ever the latter data was generated by immunoblotting
methods which lack the spatial co-localisation of pro-
tein stain to the tumour cells, a feature inherent in our
use of immunohistochemistry methodologies.We showed a high proportion of metastatic tumours
to be Cav-1 positive (69%), a result consistent with the
previous small case study of Hayakawa and co-workers
[25] reporting Cav-1 expression in 83% (5/6) of second-
ary tumours. Our clinical data revealed (Table 2) a statis-
tically significant association between Cav-1 expression
and vascular invasion (P = 0.002, n = 165) and a strong
trend in the relationship between Cav-1 expression and
capsular invasion (P = 0.06, n = 165). We therefore un-
dertook a series of in-vitro invasion assays to examine
directly if Cav-1 represents a pro-metastatic gene. Using
three human RCC cell lines derived from tumours of
clear cell origin we found Cav-1 promoted invasiveness
in all the models examined irrespective of genetic back-
ground of the cell line. This is the first report to show
that Cav-1 is an important and direct mediator of inva-
sion in bone fide human RCC cells of clear cell origin; al-
though Cav-1 status has previously been reported not to
influence the invasion of SN12CPM6 cells [38] (a RCC
cell line of mixed histology). Very recently Yamasaki
et al. [39] reported silencing of caveolin-2 (Cav-2; an-
other caveolin family member) in 786-O and A498 cells
reduced cell invasion and growth. While this is intri-
guing these workers did not evaluate the role of Cav-2
as prognostic biomarker in RCC nor did they elude to
the potential co-dependency upon Cav-1. For example,
intact caveolae are present in the 786-O cells [31,40]
with these structures appearing to be involved in NEU3-
mediated cell invasion through the regulation of β1 in-
tegrin endocytosis [40]. While Cav-1 drives the assembly
of caveolae Cav-2 can in some circumstances regulate
the size and shape of caveolae [41]. Further, the exact
scaffolding domain present within the Cav-1 molecule
that is known to interact and regulate multiple signalling
molecules is absent in Cav-2 [2].
Although our in-vitro studies unequivocally support a
role for Cav-1 in RCC invasion the impact of Cav-1
upon cell proliferation was more variable. It is however
recognised that a signal regulatory molecule can display
Figure 3 In-vitro Growth and invasion of RCC cell lines. (3A) - Cav-1 is expressed in both VHL negative and VHL positive RCC cell lines under
normoxic conditions Western blot showing comparative levels of Cav-1 protein (20 μg) expression in a panel of RCC cell lines. Blot is
representative of at least 3 independent experiments; (3B and 3C) - Typical fields of view, respectively, for control siRNA or anti-Cav-1 siRNA
treated caki-1 cells invading Matrigel coated membranes for 24 hrs and counterstained with Hoeschst 33258. Coated membranes were set up in
duplicate with the data represents the SEM of 3 different experiments; (3D, 3F, 3H) - Effect of Cav-1 silencing on RCC cell growth (mean ± SD, n = 6) and
(3E, 3G, 3I) - Effect of Cav-1 silencing on RCC cell invasion through Matrigel.
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ation in favour of increased invasion and survival in
cancer cells [42], e.g. YB-1 in breast cancer [43] and
spastin [44] in glioma, opposing properties confering a
survival advantage during the development of microme-
tastasis [42]. Our current studies in caki-1 cells (mRCC
origin) show Cav-1 to be both pro-proliferative and
pro-invasive, and may reflect the greater reliance of ad-
vanced and metastatic RCC tumours upon Cav-1 for
their patho-biology.RCC is a highly vascular tumour and previous studies
have shown a significant positive correlation between
tumour Cav-1 levels and high microvessel density [26].
We show in our in-vitro studies Cav-1 to have a partial
role in mediating the secretion of VEGF-A. Specifically,
under normoxic conditions Cav-1 elevated the secretion
of the VEGF-A from the VHL-negative 786-O and A498
cells although not from the VHL-competent caki-1 cells.
These differences may reflect the VHL status of the cells
and/or the Hif isoforms the cells’ constitutively express.
Figure 4 Effect of Cav-1 knockdown on signalling molecules in RCC cell lines. (4A) - Secretion of VEGF-A in RCC cells. Data is expressed as
mean ± SD (n = 3) and is representative of two independent experiments; (4B) - Activity of AKT/mTOR and ERK signalling pathways and
expression of the cell cycle regulators cyclinD1 and c-myc in RCC cell lines as a function of Cav-1 siRNA-mediated knockdown. Western blot is
representative of at least four independent experiments.
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786-O and A498 cells, known to be responsible for
VEGF-A production and secretion, while Hif-2α appears
to absent under normoxic in the VHL-positive caki-1
cells ([33] and our own observations). The AKT/mTOR
pathway itself has been implicated in the regulating the
expression of several key pro-angiogenic factors such as
Hif [45] and VEGF [46]. Here we found the Cav-1 medi-
ated increases in VEGF-A secretion to be independent
of PI3-K/AKT and mTOR signalling, whereas Cav-1 ap-
pears to promote both the production and release ofVEGF-A [47] in prostate cancer cells at least in part
through the potentiation of PI3-K/AKT signalling.
Using in-vitro RCC models we investigated the rela-
tionship between Cav-1 expression and other related cell
signalling pathways. Increased ERK-1/2 signalling can
promote the expression of Cav-1 in various human can-
cer cell lines including those derived from the prostate
[7] and smooth muscle [9]. In the current studies pharma-
cological inhibition of ERK signalling in the RCC cell lines
did not affect Cav-1 protein expression. This suggests the
positive correlation seen between Cav-1 and pERK-1/2 in
Figure 5 Pharmacological knockdown of signalling molecules and effect upon Cav-1 in RCC cell lines. (5A and 5B) - Effects of inhibiting
ERK upon Cav-1 and cell growth; (5C and 5D) - Effects of inhibiting TORC1 upon Cav-1 and cell growth; (5E and 5F) - Effects of inhibiting
PI3-AKT upon Cav-1 and cell growth. (5G) - Effect of RANKL on the stimulation of ERK and NF-kappaB pathways and Cav-1 expression. All above
data represent mean ± SD (n = 6) and are representative of 3 independent studies.
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an immediate downstream effector molecule of ERK-
1/2 signalling. Our in-vitro studies in the RCC cell lines
also show pERK to be maintained in the presence of
Cav-1 down-regulation. This observation is consistent
with Wang et al., [31] reporting Cav-1 to not effect the
constitutive activity (i.e. in the presence of ligand/
serum) of ERK signalling in the RCC line, 786-O. These
authors did however find Cav-1 was able to maintain
levels of pERK-1/2 under serum-deplete (ligand-inde-
pendent) conditions.We found inhibition of mTOR (TORC1) signalling to
significantly increase Cav-1 expression in the PTEN-
negative 786-O cells, but not in either of the PTEN-
positive A498 or caki-1 cell lines. The basis for this is
unclear, however, rapamycin is known to induce oxida-
tive stress in cells [48] which is exacerbated by PTEN
deletion [49]. Several oxidative stress elements that can
serve a transactivation function are contained within the
Cav-1 promoter [50]. RANKL is a common upstream ef-
fector of both ERK and NF-kappaB signalling that has
been linked with metastasis in RCC, and with cell
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examined in the in-vitro RCC models if RANKL served
as a common upstream yet parallel effector of both
pERK and Cav-1. While we saw increased activity of
both ERK and NF-kappaB signalling following RANKL
treatment, the levels of Cav-1 protein remained un-
changed. This indicates that expression of Cav-1 in the
in-vitro RCC cells was not maintained through en-
hanced NF-kappaB signalling, and that the functional
properties of Cav-1 in the in-vitro assays were not
downstream of RANKL-dependent pathways.
In summary, we demonstrate in clinically confined RCC
tumours that Cav-1 expression when combined with the
functionally relevant signalling molecule, pERK-1/2, pro-
vides a powerful prognostic biomarker able to stratify pa-
tients into low, intermediate and high-risk of metastatic
relapse, a discovery potentially useful in guiding stratifica-
tion in clinical trials and therapy. We report a significant
concordance in the expression of Cav-1 and pERK-1/2 be-
tween primary tumours and matched metastatic tissue
which supports the use of localised tumour biology to
guide therapy of non-resectable mRCC. In a panel of RCC
cell lines we provide for the first time unequivocal direct
evidence that Cav-1 can directly promote the invasion of
RCC-cell lines. We also show that Cav-1 stimulates pro-
angiogenic signals in RCC cells through its ability to en-
hance secretion of VEGF-A. The in-vitro assays showed
Cav-1 expression to be independent of ERK and AKT/
mTOR signalling. The data presented here indicate that
Cav-1 is an important biomarker and metastatic gene.
The targeting of Cav-1 may represent a future strategy for
the prevention and treatment of metastases or even
micrometastasis before the development of overt second-
ary tumours.
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